

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Quizartinib for induction, consolidation and
maintenance treatment of newly diagnosed FLT3-ITD-
positive acute myeloid leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

A stakeholder noted that while the clinical trial was conducted for the age range 18-75, NICE guidance should cover all adults for equality purposes.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The population in the scope is not restricted by age. NICE guidance typically covers all adults, in alignment with the marketing authorisation.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A

Approved by Associate Director (name): Ross Dent

Date: 19/09/2023